FDA takes risk-based approach to PAIs
This article was originally published in The Gold Sheet
Executive Summary
FDA is taking a more coordinated risk-based approach to pre-approval inspections that the agency outlined in 1compliance program guidance manual 7346.832, which took effect May 12